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Summary of methods & results 
To explore the therapeutic prospective of tar-
geting Delta-like ligand 4 (DLL4), Yan et al. 
investigated the potential side effects of block-
ing the DLL4-mediated Notch pathway in 
three animal species in nontumor-bearing 
animals [1]. Treatment of adult mice with a 
DLL4-specific antibody for 3 weeks induced 
marked histopathological changes in the liver, 
including sinusoidal dilation and centrilobular 
hepatocyte atrophy. Blockade of Notch signal-
ing by administration of an antagonistic soluble 
DLL4 (the extracellular domain of DLL4 fused 
to a human IgG1 Fc fragment), an anti-Notch1 
inhibitory antibody, or the !-secretase inhibi-
tor dibenzazepine caused similar pathological 
changes in mouse liver, suggesting an important 
role of DLL4-initiated Notch signaling in liver. 
Taking advantage of crossreaction of the DLL4 
antibody with DLL4 proteins from multiple spe-
cies, the authors then extended their studies to 
Sprague–Dawley rats and cynomolgus monkeys 
(Macaca fascicularis). Intravenous injection of 
anti-DLL4 into rats at 10 mg/kg every 3 days 
for a total of five doses or monkeys at 3 mg/kg 
once a week for a total of eight doses produced 
similar liver histopathology. 
Alterations in gene expression in the mouse 
liver were assessed 2 days after the adminis-
tration of 10 mg/kg of anti-DLL4 antibody. 
Compared with phosphate-buffered saline-
treated controls, anti-DLL4 treatment signifi-
cantly increased the expression of several genes 
by 1.5- to four-fold. These included the genes 
encoding endothelium-specific proteins EGFL7 
(an extracellular matrix protein), Esam and 
LGALS1 (a galactoside-binding protein), as well 
as DNA replication/cell cycle regulation proteins 
MCM3 and MCM7.
Serum alanine aminotransferase levels (a 
marker of hepatocyte damage) showed a signifi-
cant dose-related increase in rats treated with 
anti-DLL4 for 8 weeks at 1, 3, 10 or 30 mg/kg. 
This was associated with morphological changes 
in the liver, including marked atrophy of centri-
lobular hepatic cords, dilation of centrilobular 
hepatic sinusoids and bile ductular proliferations. 
In addition to liver, radiolabeled anti-DLL4 
antibody was shown to distribute to other 
organs, including the bone marrow, spleen and 
lung of athymic nude mice. Prominent thymic 
atrophy was also observed in immunocompetent 
animals treated with the anti-DLL4 antibody. 
More importantly, ulcerating, subcutaneous 
tumors that were typically well circumscribed 
were observed in one out of 15 male rats dosed 
at 3 mg/kg and three out 15 animals at both 
10 and 30 mg/kg for 8 weeks. These tumors 
showed numerous features of malignant vascu-
lar neoplasms, including freely anatomizing and 
branching vascular channels, focally infiltrating 
borders, necrosis, nuclear pleomorphism and a 
high proliferation fraction. Adjacent to the vas-
cular spaces were pericytes that showed immuno-
reactivity for smooth muscle actin and desmin. 
In addition to subcutaneous neoplasms, vascular 
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tumors containing regions of necrosis were infre-
quently found in the heart and lung of rats after 
anti-DLL4 antibody treatment for 8 weeks.
Discussion 
Delta-like ligand 4 is predominantly expressed 
in arterial endothelial cells during embryogen-
esis [2,3] and is markedly upregulated in the tumor 
vasculature of adult mammals [2,4–8]. Blockade of 
DLL4-mediated Notch signaling using an anti-
DLL4 antibody, soluble DLL4-Fc or a !-secre-
tase inhibitor has been shown to increase non-
productive angiogenesis, but significantly inhibit 
tumor growth in preclinical models [6,9–12]. Thus, 
DLL4 has emerged as an attractive target for can-
cer therapy [13], and anti-DLL4 antibodies have 
recently entered clinical trials. However, the 
potential side effects of blocking DLL4-mediated 
Notch signaling remain unclear. 
Yan et al. reported that, unlike the !-secretase 
inhibitor dibenzazepine, which indiscriminately 
blocks all Notch signaling, specifically targeting 
DLL4 with an anti-DLL4 antibody did not cause 
gastrointestinal toxicity [11] but produced marked 
histopathological changes in the liver of mice, 
rats and monkeys. These included centri lobular 
heptocyte atrophy, sinusoidal dilation and bile 
ductular proliferation [1]. As soon as 2 days after 
administration of the anti-DLL4 antibody, abnor-
mal activation of endothelial cells occurred in 
mouse liver, as demonstrated by increased expres-
sion of three endothelium-specific genes and two 
genes concerned with DNA replication and cell 
cycle regulation. In keeping with these observa-
tions, treatment of rats with an anti-DLL4 anti-
body for 8 weeks was associated with a rise in the 
serum alanine aminotransferase levels, suggesting 
hepatocyte injury. Unfortunately, it is difficult to 
form a unifying hypothesis that the endothelial 
dysfunction seen in the mice is responsible for 
the hepatocyte toxicity seen in the rats. Complete 
experiments conducted within a single species are 
required to fully evaluate the clinical significance 
of these findings and the reversibility of both the 
endothelial dysfunction and hepatocyte injury.
No lethality was observed in mice and rats 
after 12 weeks of anti-DLL4 treatment [1]. 
However, DLL4 is abundantly expressed in the 
nervous system, the gastrointestinal system and 
the thymus during embryonic development [14], 
as well as in smaller arteries and microvessels 
in adult mice [14,15]. Prominent thymic atrophy 
was also evident in immunocompetent animals 
treated with anti-DLL4 antibody, consistent 
with the expression of DLL4 in thymic epithe-
lial cells and the function of DLL4 in T-cell 
lineage commitment in thymus [16]. However, 
the presence of radiolabeled anti-DLL4 antibody 
in vessel-rich organs, such as the liver, bone mar-
row, spleen and lung (in athymic nude mice) was 
to be expected and does not necessarily imply 
toxicity [1]. Pathological and functional effects 
of chronic DLL4 blockade on other important 
organs, such as brain, kidney, lung and bone 
marrow, were not described.
Surprisingly, Yan et al. found that chronic 
DLL4 blockade was associated with the devel-
opment of vascular neoplasms in rats in a dose-
related manner. To be considered malignant, 
evidence is required to show that the tumors do 
not show involution on the discontinuation of 
DLL4 blockade and show aggressive local inva-
sion and/or distant metastasis, which was not the 
case here. Nevertheless, the features described by 
Yan et al. would be consistent with a diagnosis 
of angiosarcoma in a human endothelial cell 
neoplasm. Indeed, the description of the cellular 
areas of these tumors is reminiscent of epitheli-
oid differentiation, a feature of highly aggressive 
angiosarcomas. The distinction is important, as 
angiosarcomas that are not amenable to surgical 
excision have an exceptionally poor prognosis and 
those that are excised have a high recurrence rate. 
These observations were not reported in other 
species, such as mice and monkeys, and a histo-
pathological study of the natural history of these 
tumors with continued therapy and on cessation 
of therapy is critical to inform their behavior.
We investigated the expression of DLL4 in 
several human cancers, including kidney, blad-
der, brain, colorectal and breast tumors [4–8]. To 
further explore the role of DLL4 in endothelial 
neoplasms, we examined the expression of DLL4 
by immunohistochemistry in 16 human angio-
sarcomas [4]. Immunoreactivity for DLL4 was 
observed in the malignant cells of four out of 
seven breast, one out of one duodenal, one out of 
one liver, two out of five skin, one out of one pleu-
ral and zero out of one vaginal angio sarcomas. 
Immunoreactivity for DLL4 was strongest in the 
malignant endothelial cells of well -differentiated 
angiosarcomas showing prominent vascular 
channels (FIGURE 1A & B). In several poorly differ-
entiated areas with an epithelioid morphology 
(FIGURE 1C), the malignant cells were negative for 
DLL4 expression, in contrast to the strongly 
positive intervening vascular channels. Thus, 
DLL4 may have been a tumor suppressor gene 
in the etiology of some angiosarcomas that do not 
express DLL4. However, in other angiosarcomas 
that commonly express DLL4, DLL4 could be 
the direct target for therapy. 
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Conclusion & future perspective 
Delta-like ligand 4 is strongly upregulated in 
tumor-associated endothelium and a small 
proportion of tumor cells in glioblastomas [6], 
colorectal adenomas/adenocarcinomas [5] and 
breast carcinomas [4]. Therefore, treatment with 
an anti-DLL4 antibody at a therapeutic level 
should preferentially bind to the tumor cells and 
tumor endothelial cells compared with normal 
tissue. It will be essential to investigate whether 
similar pathological changes would be produced 
by an anti-DLL4 antibody in tumor-bearing ani-
mals using doses that are optimally therapeutic, 
particularly studying organs such as the brain, 
liver, kidney, lung and bone marrow. 
Chronic DLL4 blockade was associated with 
the development of subcutaneous neoplasms 
with uncertain malignant potential that have 
a vascular architecture [1]. It will be interesting 
to investigate whether these tumors are revers-
ible after cessation of DLL4 blockade. It is not 
clear whether the development of vascular neo-
plasms is dependent upon the host gender and 
species. It would be informative to address the 
question using different strains of mice, rats 
and monkeys. 
Single-agent antiangiogenic therapy, for 
example, anti-VEGF agents, shows compara-
tively poor activity and efficacy compared with 
combination therapy with cytotoxic agents in 
preclinical models and clinical trials [13]. Indeed, 
the combination of disrupted DLL4/Notch 
signaling with either blockade of the VEGF 
pathway or cytotoxic chemotherapy has shown 
a robust synergistic inhibition of tumor growth 
in preclinical mouse models [9,13]. Thus, disrup-
tion of both DLL4/Notch and VEGF pathways 
or use of a combination of anti-DLL4 and cyto-
toxic agents (e.g., irinotecan and paclitaxel) may 
have not only improved the therapeutic efficacy 
of DLL4 blockade but may have also prevented 
the induction of vascular neoplasms. Using such 
combinations, particularly anti-VEGF therapy, 
in the model will be of major interest, to see 
if this prevents the development of the lesions.
Clearly, the reported toxic effects of this 
anti-DLL4 antibody in multiple organs and 
the induction of vascular neoplasms need to be 
confirmed in different tumor-bearing animals. 
This risk versus a clear antitumor benefit will 
need to be addressed in future trials. For the 
present, awareness of this issue should be taken 
into account in clinical monitoring of trials that 
are evaluating anti-DLL4 agents. However, it is 
important that the reversability or progression 
of these lesions is investigated.
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Figure 1. Immunohistochemistry showing 
DLL4 expression (brown membranous 
staining with diaminobenzidine against a 
blue nuclear hematoxylin counterstain). 
(A) a well-differentiated breast angiosarcoma, 
(B) a well-differentiated skin angiosarcoma and 
(C) an area of epithelioid morphology in a 
pleural angisarocoma (asterix: malignant 
epitheloid angiosarcoma cells that are negative 
for DLL4; arrow: intervening vascular channels 
that are positive for DLL4).
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